Colossal Biosciences Targets $30 Billion Valuation as Deep Tech Investment Accelerates Across America

Colossal Biosciences is reportedly seeking fresh funding at a valuation between $20 billion and $30 billion, signaling continued investor confidence in deep-tech innovation and biotechnology. The Texas-based startup, known for its ambitious de-extinction projects, has quickly become one of the most closely watched companies in the U.S. startup ecosystem.

Founded in 2021, Colossal initially gained global attention for its efforts to revive extinct species such as the woolly mammoth, dire wolf, and dodo bird. However, the company’s business has expanded far beyond de-extinction. It is now commercializing technologies in conservation, computational biology, artificial intelligence, and genetic engineering, creating multiple revenue opportunities.

Over the past year, Colossal has also launched several spinout companies focused on biotechnology and AI-powered life sciences while partnering with governments and conservation organizations on wildlife protection initiatives. These diversified ventures have strengthened its commercial outlook and attracted growing investor interest.

The latest fundraising discussions reflect the broader momentum in America’s deep-tech sector, where breakthroughs in biotechnology, climate innovation, and AI continue to attract significant venture capital. If completed, the new funding round would rank among the largest biotech investments in recent years and further establish Colossal as a leader in next-generation scientific innovation.

As demand for transformative technologies grows, Colossal Biosciences is positioning itself at the intersection of science, sustainability, and commercial innovation, helping shape the future of biotechnology in the United States.